Abstract:Network-based computational method, with the emphasis on biomolecular interactions and biological data integration, has succeeded in drug development and created new directions, such as drug repositioning and drug combination.Drug repositioning, that is finding new uses for existing drugs to treat more patients, offers time, cost and efficiency benefits in drug development, especially when in silico techniques are used.MicroRNAs (miRNAs) play important roles in multiple biological processes and have attracted much scientific attention recently.Moreover, cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs.At the same time, human diseases result from the disordered interplay of tissue-and cell lineage-specific processes.However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity.Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases.Firstly, based on miRNAs data, target genes and information of FDA (Food and Drug Administration) approved drugs, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI (protein-protein) network.Then, we construct a tripartite network: drug-miRNA-disease Finally, we obtain the potential drug-disease associations based on the tripartite network.In this paper, we take breast cancer as case study and focus on the top-30 predicted drugs.25 of them (83.3%) are found having known connections with breast cancer in CTD (Comparative Toxicogenomics Database) benchmark and the other 5 drugs are potential drugs for breast cancer.We further evaluate the 5 newly predicted drugs from clinical records, literature mining, KEGG pathways enrichment analysis and overlapping genes between enriched pathways.For each of the 5 new drugs, strongly supported evidences can be found in three or more aspects.In particular, Regorafenib (DB08896) has 15 overlapping KEGG pathways with breast cancer and their p-values are all very small.In addition, whether in the literature curation or clinical validation, Regorafenib has a strong correlation with breast cancer.All the facts show that Regorafenib is likely to be a truly effective drug, worthy of our further study.It further follows that our method miTS is effective and practical for predicting new drug indications, which will provide potential values for treatments of complex diseases.

Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk

Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression.

Predicting Therapeutic Drugs for Hepatocellular Carcinoma Based on Tissue-Specific Pathways

Predicting therapeutic and aggravating drugs for hepatocellular carcinoma based on tissue-specific pathways

Discovery of new drug therapeutic indications from gene mutation information for hepatocellular carcinoma

Identifying Potential Drug Targets in Hepatocellular Carcinoma Based on Network Analysis and One-Class Support Vector Machine.

Predicting potential treatments for complex diseases based on miRNA and tissue specificity

Predicting Drug-Induced Hepatotoxicity Based on Biological Feature Maps and Diverse Classification Strategies

A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma

Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity

Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma

Author Correction: Prediction of New Drug Indications Based on Clinical Data and Network Modularity

Predicting Effective Drug Combinations for Cancer Treatment Using a Graph-Based Approach

Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma

Prediction and Analysis of Hepatocellular Carcinoma Related Genes Using Gene Ontology and Kegg

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

Prediction of clinical prognosis and drug sensitivity in hepatocellular carcinoma through the combination of multiple cell death pathways

Identifying Breast Cancer-Related Genes Based on a Novel Computational Framework Involving KEGG Pathways and PPI Network Modularity

A Novel Target Convergence Set Based Random Walk with Restart for Prediction of Potential LncRNA-disease Associations

Random-forest Algorithm Based Biomarkers in Predicting Prognosis in the Patients with Hepatocellular Carcinoma

Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma